131002-01-2

Basic information

• Product Name: 2-Bromo-4-chlorobenzamide
• Synonyms: 2-Bromo-4-chlorobenzamide
• CAS NO: 131002-01-2
• Molecular Formula: C₇H₅BrClNO
• Molecular Weight: 234.4777
• Mol File: 131002-01-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Bromo-4-chlorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-chlorobenzamide(131002-01-2)
• EPA Substance Registry System: 2-Bromo-4-chlorobenzamide(131002-01-2)

Safety Data

• Hazardous Substances Data: 131002-01-2(Hazardous Substances Data)

Upstream product

• 619-56-7 4-chlorobenzamide 
• 936-08-3 2-bromo-4-chlorobenzoic acid 
• 57381-49-4 2-bromo-4-chloro-benzonitrile 

Downstream Products

• 131002-04-5 4-chloro-2-ethenylbenzamide 
• 934180-42-4 2-(benzylthio)-4-chlorobenzamide 
• 1339650-77-9 4-chloro-2-mercaptobenzonitrile 
• 127033-30-1 (E)-7-chloro-2-styrylquinazolin-4(3H)-one 
• 7012-94-4 7-chloro-5-methyl-2-phenylquinazolin-4(3H)-one 
• 131002-09-0 6-chloroisoquinolin-1(2Η)-one 
• 263845-82-5 2-bromo-4-hydrazinylbenzonitrile 
• 16889-21-7 3-amino-6-chloro-1H-indazole 
• 57381-49-4 2-bromo-4-chloro-benzonitrile 

Relevant articles and documents

Acid-promoted palladium(II)-catalyzed ortho-halogenation of primary benzamides: En route to halo-arenes

Br?nsted acid-promoted palladium(II)-catalyzed regioselective installation of halogens (Br, Cl, and I) to the aromatic ring of benzamide derivatives has been achieved using primary amides. A wide variety of benzamides were compatible under established conditions to afford the halogenated products without installing any external auxiliary. Mild reaction conditions, use of primary amide as a directing group, external additive-free conditions, and gram-scale reaction are some appealing features of this protocol. Detailed experimental results revealed that Br?nsted acid plays a critical role in this transformation.

FACTOR XIA INHIBITORS

The present invention provides a compound of Formula I(The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.